Clinical Trials Logo

Clinical Trial Summary

This is a multicentre, active-control randomized, prospective, Phase 3 study in adult cardiac surgery patients. Approximately 500 patients will be randomized at approximately 12 hospitals.


Clinical Trial Description

Patients will be randomized to receive either 4-factor PCC (Octaplex) or frozen plasma (FP). The study will compare the hemostatic treatment response to Octaplex versus FP, defined as effective if no additional systemic or surgical hemostatic intervention is required from 60 minutes to 24 hours after initiation of the first treatment dose. The study will include adult (≥18 years old) patients who undergo cardiac surgery with cardiopulmonary bypass (CPB) and require coagulation factor replacement due to bleeding post-CPB and after adequate reversal of heparin with protamine (as assessed by the surgical staff based on clinical and laboratory criteria) during surgery, and who have a known (e.g., as indicated by INR) or suspected coagulation factor deficiency. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05523297
Study type Interventional
Source Octapharma
Contact Sigurd Knaub
Phone +41795330529
Email Sigurd.Knaub@Octapharma.com
Status Recruiting
Phase Phase 3
Start date November 10, 2022
Completion date August 2024